Список проголосовавших за комментарий " On The Wires<ul><li>Petrobras (<strong>PBR</strong>) informs that it received today a Letter No. 33/2017/CVM/SEP/GEA-5, following a meeting of the Brazilian Securities and Exchange Commission (CVM) that took place today, in which CVM's Collegiate decided to publish the Letter No. 30/2017/CVM/SEP/GEA-5 («Letter No. 30»), dated March 3, 2017, through which CVM's technical area determined «the re-making, re-presentation and re-statement of the complete annual financial statements for the periods ending on December 31, 2013, December 31, 2014, and December 31, 2015, and the re-making and re-presentation of the respective DFP Forms, as well as the restatement and re-presentation of the ITR Forms presented in the course of the fiscal years of 2013 (2nd and 3rd), 2014, 2015 and 2016, considering the reversals of recognized accounting effects arising from the application of hedge accounting.»</li><li>BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces it has entered into a collaborative agreement with Merck & Co. (<strong>MRK</strong>), through a subsidiary, focused on the clinical evaluation of BGB324 with KEYTRUDA (pembrolizumab) in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Under the terms of the collaboration with MSD, BerGenBio will conduct two international Phase II studies to evaluate the potential clinical synergy of combining BGB324 with MSD's anti-PD-1 therapy, KEYTRUDA.</li><li>Stratasys Ltd. (<strong>SSYS</strong>) announced enrollment is now open for 3DHEART, an investigator initiated trial. 3DHEART, which stands for 3D Hearts Enabling ARandomized Trial, is a randomized, single-blind clinical trial to study the use of patient-specific 3D printed models in pre-operative planning for pediatric heart surgery.</li></ul>"